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ADAM10, the rate-limiting protease of regulated intramembrane
proteolysis of Notch and other proteins, is processed by
ADAMS-9, ADAMS-15, and the gamma-secretase
Abstract
ADAM10 is involved in the proteolytic processing and shedding of proteins such as the amyloid
precursor protein (APP), cadherins, and the Notch receptors, thereby initiating the regulated
intramembrane proteolysis (RIP) of these proteins. Here, we demonstrate that the sheddase ADAM10 is
also subject to RIP. We identify ADAM9 and -15 as the proteases responsible for releasing the
ADAM10 ectodomain, and Presenilin/gamma-Secretase as the protease responsible for the release of the
ADAM10 intracellular domain (ICD). This domain then translocates to the nucleus and localizes to
nuclear speckles, thought to be involved in gene regulation. Thus, ADAM10 performs a dual role in
cells, as a metalloprotease when it is membrane-bound, and as a potential signaling protein once cleaved
by ADAM9/15 and the gamma-Secretase.
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ADAM10 is involved in the proteolytic 
processing and shedding of proteins such as
the Amyloid Precursor Protein (APP), 
Cadherins and the Notch receptors, thereby 
initiating the regulated intramembrane 
proteolysis (RIP) of these proteins. Here, we 
demonstrate that the sheddase ADAM10 is 
also subject to RIP. We identify ADAM9 and 
-15 as the proteases responsible for releasing 
the ADAM10 ectodomain, and Presenilin/-
Secretase as the protease responsible for the 
release of the ADAM10 intracellular domain 
(ICD). This domain then translocates to the 
nucleus and localizes to nuclear speckles, 
thought to be involved in gene regulation. 
Thus, ADAM10 performs a dual role in cells, 
as a metalloprotease when it is membrane-
bound, and as a potential signalling protein 
once cleaved by ADAM9/15 and the γ-
Secretase. 
ADAMs (A Disintegrin And Metalloprotease) 
are type 1 transmembrane proteins related to 
snake venom integrin ligands and 
metalloproteases. All 38 different family 
members feature a common modular ectodomain 
structure [1-4] (Fig 1 A). In addition to the 
membrane-bound, full-length prototype, soluble 
ADAM variants have also been identified, 
consisting of only the ectodomain or fragments 
thereof that are released into the intercellular 
space. Such variants are generated by partial 
gene duplication (ADAM9) [5], alternative 
splicing (ADAM12) [6, 7] or proteolysis 
(ADAMs 8, 13 and 19) [8-10]. ADAMs can be 
grouped either by their tissue distribution and/or 
functional properties. One major group (ADAMs 
2, 3, 5, 6, 16, 18, 20, 21, 24, 25, 26, 29, and 30) 
is expressed exclusively in the male gonad, with 
an emerging role in sperm maturation.  A second 
group (ADAMs 2, 7, 11, 18, 22, 23, 29) is 
characterized by an inactive protease domain, 
and they seem to be mainly important for cell 
adhesion and fusion. A large third group of 
 http://www.jbc.org/cgi/doi/10.1074/jbc.M805894200The latest version is at 
JBC Papers in Press. Published on February 11, 2009 as Manuscript M805894200
 Copyright 2009 by The American Society for Biochemistry and Molecular Biology, Inc.
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 5, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
2ADAMs displays a broad expression profile and 
has demonstrated (ADAMs 8, 9, 10, 12, 17, 19, 
28) or predicted (ADAMs 15, 20, 21, 30 and 33) 
proteolytic activity. These proteases play a major 
role in the ectodomain shedding of proteins 
involved in paracrine signaling, cell adhesion 
and intracellular signaling (reviewed in [11, 12]). 
The site specificity of the cleavage of these 
substrates is rather relaxed, and apparently 
different family members can mutually 
compensate for each other. This has been 
illustrated particularly well for the Amyloid 
Precursor Protein (APP) [13-17]. 
ADAM10 is one of the proteolytically active 
ADAM members [15, 18-21]. The list of 
ADAM10 substrates is still growing, confirming 
the central role of ADAM10 in many important 
biological processes, such as cell migration and 
axonal navigation (robo receptors and ephrins 
[22, 23], cell adhesion (cadherins [19, 21], CD44 
and L1 [24]) and regulation of immune 
reactions, and control of apoptosis (FasL) [25]. 
Importantly, genetic ablation of ADAM10 in 
vertebrates [15] and invertebrates [26-29] mainly
results in loss of Notch phenotypes, indicating 
the crucial role for this protease in the Notch
signalling pathway [30, 31]. Finally, ADAM10 
is emerging as a major player in human disease. 
It is upregulated in several tumours [32], and it is 
also considered to be protective in Alzheimer’s 
disease (AD) as it is one of the major -
secretases, cleaving APP within the amyloid-
beta (Aβ) peptide sequence, which thus 
precludes amyloid plaque formation [13, 18, 20, 
33]. Interestingly, two other ADAMs (9 and 17) 
have also demonstrated –secretase activity in 
vitro [13, 14, 16, 18]. Thus, stimulating -
secretase cleavage is an interesting therapeutic 
option for AD [20]. 
A fascinating aspect of ADAM10 – mediated 
proteolysis is the initiation of regulated 
intramembrane proteolysis (RIP), which is 
characterized by two consecutive cleavage steps. 
First, the ectodomain is shed to generate a 
soluble ectodomain [11, 34]. Then, the 
remaining transmembrane C-terminal fragment 
(CTFs) becomes a substrate for intramembrane 
cleaving proteases such as Presenilin/γ-Secretase 
[35]. The fragments generated by this cleavage 
are released both externally and internally from 
the membrane and are, in many instances,
involved in cell signalling pathways. Notch 
signalling has been particularly well investigated 
and it is well known that the Notch intracellular 
domain, upon release by Presenilin/γ-Secretase, 
translocates to the cell nucleus and regulates
transcription of a series of Notch target genes in 
so-called transcription factories [36-41].
Presenilin (PS), an aspartyl protease, is the 
catalytic subunit of the -Secretase complex [42, 
43]. Two different genes encode PS1 and PS2 
respectively, which each integrate into different 
γ-Secretase complexes [44]. Although many -
Secretase substrates have been discovered 
(reviewed by Kopan [35]), the extent to which 
the released intracellular domain fragments are 
important for signalling is not completely clear
as most of the work is based on in vitro
experiments. Thus, the possibility exists that, in 
many cases, the -Secretase could act as an 
‘intramembrane proteasome’, removing residual 
transmembrane protein fragments that were 
generated by for instance ectodomain shedding 
mediated by ADAM members, to avoid creating 
a bottleneck in the plasma membrane [35].
Here we demonstrate the surprising finding that 
ADAM10, apart from its central role in protein
shedding and the initiation of regulated 
intramembrane proteolysis of several substrates, 
is itself subject to a similar proteolytic cascade. 
This suggests that ADAM10 has, in addition to 
its important function as a membrane-tethered 
sheddase, also the potential to be a signal 
transducing protein itself. 
EXPERIMENTAL PROCEDURES
Animals, cell cultures and tissues
Mice and derived cell lines and the technique 
used for their derivation and maintenance were 
published before [17, 45, 46]. Primary murine 
glial and cortical neuronal cultures were 
established from brains of embryonic day 14.5 
mice, as described previously [47].
cDNA constructs  
Full-length murine ADAM9 and ADAM15 as 
well as ADAM9EA and ADAM15EA catalytically 
inactive mutant constructs, were kind gifts from 
C.P. Blobel [48, 49]. ADAM10 cDNA (complete 
cds of GenBank sequence AF011379) was 
obtained by PCR from a murine 129/SvJ c-DNA 
library and was recloned into a modified PSG5 
expression vector (Stratagene). A VP16-Gal4 
sequence [50] was subcloned into mADAM10
cDNA after introduction of an HpaI restriction 
site in the ADAM10 C-terminus via site directed 
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3mutagenesis (Stratagene) at positions G745V, 
H746N. A mADAM10 construct lacking the 
ectodomain (containing a signal peptide 
sequence (AA1-19) joined to AA669-749) was 
flag-tagged 
(CTTGTCATCGTCGTCCTTGTAGTC) before 
the stopcodon at the C-terminus. The PCR 
product was ligated into a pcDNA3.1 vector 
(ADAM10E-flag). All constructs were 
sequenced and contained no errors. For COS and 
HEK293 cell transfections we used Fugene6 
(Roche) or Genejuice (Merck Biosciences), 
according to manufacturer’s protocol.
Sample preparation
Cell extracts were obtained as described before 
[15]. Phenanthroline was added to the protease 
inhibitor cocktail to prevent autocleavage during 
extraction procedure, as previously described for 
TACE [51]. The -Secretase inhibitor X 
(carbamic acid tert-butyl ester L-685,458, 
Calbiochem) was used at 0.1µM in medium with 
2% FCS, unless otherwise specified [52]. 
Shedding Assay After 24 h of serum-starvation 
[53] culture medium was replaced with fresh 
serum-free medium containing one of the 
following protease inhibitors (Calbiochem): 
TAPI-1 (25µM), TAPI-2 (25µM), GM6001 (50 
µM), or the appropriate vehicle control.  
Following 24h incubation cell viability was 
checked, cell extracts were obtained and cell 
culture supernatants were concentrated 20x by 
ultrafiltration (Centricon-10/ Millipore). 
α - Secretase FRET assay. Cell extracts and 
concentrated supernatant of ADAM10-/- and WT 
MEFs, after overnight conditioning in SFM, 
were incubated with a fluorogenic substrate 
peptide mimicking the APP α-secretase cleavage 
site as indicated by the manufacturer (R&D). 
Fluorogenic emission was measured by Victor2 
(PerkinElmer) at 495 nm.
Membrane extracts and whole protein extracts 
were prepared as described previously [53]. 
Subcellular fractionation. Postnuclear 
supernatants (PNS) were prepared using a 
sucrose step gradient protocol (adapted from 
Fleischer & Kervina, [54]). Pooled cells from 
five 10cm culture dishes, after 1.5h treatment 
with 20ng/ml leptomycin B (LMB, Sigma)(52), 
were harvested and homogenized in ice-cold 
buffer (20mM Hepes-NaOH, pH 7.4, 5mM 
MgCl2, 0.25M sucrose with 0,2M DTT, protease 
inhibitors, without EDTA) using a Glass Dounce 
Homogenizer (Type S). Cell disruption and 
integrity of nuclei was checked. SHM2.1 (20mM 
Hepes-NaOH, pH 7.4, 5mM MgCl2, 2.1M 
sucrose) was added to the homogenate to obtain 
a final sucrose concentration of 1.5M and after 
centrifugation at 29000rpm (TST41), the pellet 
was resuspended in SHM 0.25 (20mM Hepes-
NaOH, pH 7.4, 5mM MgCl2, 0.25M sucrose). 
Fractions were collected and analyzed by 
Western blotting. 
SDS-PAGE Proteins were separated and 
transferred as described before [15]. Primary 
antibodies (O.N. 4°C) and HRP – tagged (Dako) 
secondary antibodies  (1h R.T.) were applied. 
ADAM10 was detected using the polyclonal 
antiserum (B 42.1), generated against the 17 C-
terminal amino acid residues [15]. N-terminal 
specific antibody MAB946 (R&D) only detected 
ADAM10 when sample buffer contained 1µM 
N-Ethylmaleimide (NEM) (Pierce) instead of β-
mercaptoethanol [55]. APP fragments, PS1, PS2 
and ADAM15 were detected respectively using 
antibodies B63.1, B19.3, B22.4 and SM86-2, as 
described previously [56, 57]. ADAM9 and Sp1 
(Santa Cruz),  actin (Sigma) were detected by 
commercial antisera. Blots were developed using 
the ECL Detection System (Amersham) or 
Supersignal (Pierce). Signal densities were 
quantified (in the linear range) with Totallab 
v2.01 (Molecular Dynamics). 
Luciferase assay. COS cells were transfected 
with 200 ng pFRluc plasmid (Promega) DNA 
and 200 ng inducer plasmid DNA: ADAM10-
VP16-GAL4, APP-C99-GAL4-VP16, GAL-
VP16 or empty vector. The GAL4-VP16 
construct without a membrane anchor was used 
as a -Secretase independent positive control. 
After 24 h, cells were incubated with or without 
inhibitor X, and after 16 h were lysed and 
assayed (Victor2; PerkinElmer) [53]. 
Confocal laser scanning microscopy. HEK293 
cells transfected with ADAM10E-flag were 
fixed after 24 h in 1% PFA (10’, R.T.), 
permeabilized by methanol (–20°C) or 0.5% 
Triton X-100/PBS (5’), and processed for 
indirect immunofluorescence [50]. Primary 
antibodies (O.N. 4°C) and Alexa-488 or –568 
conjugated (Molecular Probes, Inc) or Cy3-
(shown in red) or Cy2-conjugated (shown in 
green) (Jackson ImmunoResearch) secondary 
antibodies  (1h R.T.) were applied and nuclei 
were counterstained using Hoechst Bisbenzimid 
H33342 (Sigma) (10’ R.T.). Monoclonal M2 and 
polyclonal anti-FLAG antibodies, as well as 
antibodies detecting PML, coilin, BrdU and 
nucleophosmin/B23 were purchased from 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 5, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
4Sigma. Antibodies against lamin B and sc-35 
were purchased from Santa Cruz and BD 
Transduction Laboratories, respectively. 
Coverslips were mounted using Mowiol 
(Calbiochem). After staining, cells were 
examined using an inverted microscope (Eclipse 
E800, Nikon; Plan Apo 60x/1.40oil) connected 
to a confocal microscope (Radiance 2100; Zeiss 
or Leica SP2) and images were acquired using 
LaserSharp 2000 software. Images were 
processed in Adobe Photoshop CS. Speckled 
nuclei were defined as cells containing 3 or more 
large or 5 or more small granular ‘speckle-like’ 
structures in their nucleus. 100 Flag-positive 
cells were counted manually in a blind fashion to 
quantify the effect of -Secretase inhibition 
(O.N. 37°C). The number of speckled cells 
(mean of 3 experiments) is indicated as a 
percentage of the amount of ADAM10E-flag 
transfected cells. 
Statistical analysis. Data were subjected to 
statistical analysis (one-way ANOVA with a 
Bonferroni correction) to determine their 
significance. P values are demonstrated in the 
figures using asterisks (*:p<0.05; **:p<0.01; 
***:p<0.001).
RESULTS
The ADAM10 ectodomain is shed from 
fibroblasts in vitro
In Western blots of whole cell homogenates,
ADAM10 appears as a doublet band of ~ 85 and 
65 kDa, corresponding to the unprocessed pro-
form and the mature enzyme, respectively [58]. 
In addition a band at ~ 10 kDa is observed that 
reacts exclusively with carboxyterminus-specific 
antibodies (ADAM10 CTF, Fig 1 A-B). It is 
noteworthy that in some experiments the 
ADAM10 CTF appears as a doublet band (e.g. 
Fig 2 B, panel 4). In the culture supernatant 
samples of the cells, we also observed a soluble 
protein at ~55 kDa that was immunoreactive 
with antibodies against the ADAM10 amino- but 
not carboxyterminus (soluble = sADAM10, Fig 
1 B). These bands were undetectable in cell 
extracts and supernatants from ADAM10 -/-
MEFs (Fig 1 B). Thus, ADAM10 is apparently 
processed by an unknown protease generating a 
membrane- bound carboxyterminal fragment and 
a secreted, soluble ectodomain. We checked 
whether the ADAM10 ectofragment shedded in 
the medium retained its proteolytic activity. The 
supernatant of wild-type MEFs cleaves a 
synthetic peptide containing the α-secretase 
cleavage site of APP in a FRET assay. This 
activity is strongly reduced in supernatant of 
MEFs lacking ADAM10 (Fig 1 C). In separate 
experiments we could demonstrate that removal 
of ADAM10 from the supernatant by 
immunoprecipitation also reduces significantly 
proteolytic activity (data not shown).
ADAM10 CTFs were also observed in cell 
lysates of cultured neurons and astrocytes (Fig 1 
D) and in vivo in brain, liver, lung, heart and 
kidney tissue from both embryo- (Fig 1 E) and 
adult mice (data not shown). As shown in Fig 1 
E, considerable differences in ADAM10 
processing are observed in different tissues. In 
particular the heart (which is strongly affected 
by ADAM10 deficiency, see [15]) displays an 
abundant accumulation of the ADAM10 CTF. 
ADAM10 shedding depends on ADAMs 9 and 
15
To identify the proteases responsible for 
ADAM10-shedding, we screened wild-type 
MEF cultures with a panel of inhibitors against 
all major classes of proteases, but only the
metalloprotease inhibitors GM6001, TAPI1 and 
TAPI2 reduced ADAM10 CTF and sADAM10 
accumulation in MEFs, suggesting that the 
ADAM10 sheddase(s) belong(s) to the 
metalloprotease family (Fig 2 A).  Members of 
the ADAM family are known to be important 
ectodomain shedding metalloproteases. So far, 
only 12 of the 38 ADAMs have a demonstrated 
(ADAMs 8, 9, 10, 12, 17, 19, 28) or predicted 
(ADAMs 15, 20, 21, 30 and 33) active MP 
domains. Consequently, we investigated 
ADAM10 shedding in MEF cell lines deficient 
in expression of ADAMs 9, 15, 19 and cell lines 
deficient for both ADAMs 9 and -15. We found a 
significant, albeit somewhat variable, reduction 
in ADAM10 shedding in ADAM9 deficient MEF 
lines (Fig 2 B, panels 4 and 7, lanes 4-6), whilst 
shedding was virtually abolished in a cell line 
lacking both ADAMs 9 and -15 (Fig 2 B, panels 
4 and 7, lanes 7-9). No difference in ADAM10
shedding was observed in ADAM19-/- MEFs 
(data not shown). We confirmed that ADAM10 
is a novel substrate for ADAM9 and ADAM15 
by overexpression experiments in COS cells.
Only low amounts of endogenous ADAM10 
holoprotein and no CTFs could be detected in 
untransfected cells (Fig 2 C, panels 1 and 3, 
lanes 1-2). However, upon transient 
overexpression of ADAM10 an intense doublet 
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5band of ADAM10 FL as well as ADAM10 CTF 
and the soluble ADAM10 ectodomain were 
observed (Fig 2 C, panel 1 and 3, lanes 5-7). 
When increasing amounts of ADAM9 (0.1g in 
Fig 2 C, panel 2, lanes 14-15 versus 1g in 
lanes 8-10) were co-overexpressed with 
ADAM10, more ADAM10 fragments were 
generated (Fig 2 C, panels 3 and 6; lanes 14-15 
and lanes 8-10, respectively), whilst this effect 
was undetectable following transfection with
similar concentrations of the catalytically 
inactive ADAM9EA mutant (Fig 2 C, lanes 16-
17 and 11-13). A similar increase in sADAM10 
was shown when ADAM15, but not ADAM15EA,
was overexpressed in COS cells, demonstrating
the ability of ADAM15 to cleave ADAM10 as 
well. Interestingly, accumulation of the cell-
bound ADAM10 CTF was not observed 
following cleavage by ADAM15 (supplemental 
Fig 1), whereas it is a consistent feature of 
ADAM9-mediated cleavage. Although the 
precise mechanism is unclear, the observed 
absence of the ADAM10 CTF following 
cleavage by ADAM15 cleavage suggests the 
ADAM10 CTF is rapidly degraded after 
proteolytic processing by ADAM15. 
Finally, we sought to determine whether 
ADAM9 and 15 are involved in ADAM10 
proteolytic processing in vivo. Thus, we 
examined ADAM10 CTF generation in ADAM9-
and ADAM9/15-deficient mouse brain samples 
from different postnatal ages (Fig 2 D). We 
observed a decrease in ADAM10 CTF 
generation in the ADAM9- and ADAM9/15-
deficient mouse brain samples relative to WT 
control samples, demonstrating in vivo
correlation of the in vitro cell culture studies 
conducted in MEF and COS cell lines. 
Interestingly, the reduction in ADAM10 CTF 
generation was less prominent in tissues such as 
the liver and lung (unpublished observations), 
which suggests the presence of additional tissue-
specific ADAM10 sheddases. 
Apparently, the deficiency of ADAM10 
shedding did not result in the accumulation of 
full length ADAM10, indicating a tight control 
of ADAM10 holoprotein levels in the cell.
ADAM10 CTFs are cleaved by -Secretase to 
release a free intracellular domain 
In many instances, the carboxyterminal 
fragments (CTF) of type I integral membrane 
proteins generated by ectodomain shedding are 
subsequently cleaved by γ-Secretase, a protein 
complex that contains Presenilin as the catalytic 
subunit. Therefore, we determined whether the 
ADAM10 CTFs generated by ADAM9 and 15 
are also substrates for -Secretase (Fig 3 A). 
Inhibiting γ-Secretase activity with the -
Secretase inhibitor X resulted in an accumulation 
of ADAM10 CTFs in wild-type cells (Fig 3 B).
In accordance with this finding, there was a clear 
accumulation of ADAM10 CTF fragments in 
PS1 and PS1/PS2 double deficient MEFs (Fig 3 
C, lanes 2 and 4 or 6). Interestingly, the pattern 
of ADAM10 CTF accumulation in these cell 
lines is very similar to the CTF accumulation 
observed with other -Secretase substrates, such 
as APP and Notch, in agreement with the 
conclusion that the ADAM10 CTF is a valid 
substrate for γ-Secretase. Additional studies 
utilizing genetic rescue experiments with wild-
type human PS1, but not a PS1 active site 
mutant, confirmed that ADAM10 CTF is an 
authentic γ-Secretase substrate (Fig 3 C, lanes 7-
9). . 
We confirmed the role of the γ-Secretase in 
ADAM10 CTF turnover in vivo, by determining 
ADAM10 CTF generation in various tissues 
from PS1- and PS2-deficient mice. ADAM10 
CTF accumulation was established in brain, 
lung, liver, heart and kidney from E 16.5 PS1-/-
and PS2-/- mice. ADAM10 CTF accumulation 
was prominent in the brain and lung of PS1-
deficient mice whereas ADAM10 CTF 
accumulation was the highest in the liver of PS2-
/- mice, exceeding the deficit in ADAM10 CTF 
processing observed in PS1-/- mice (Fig 3 D).
Intriguingly, the liver displays the highest levels 
of PS2 expression in wild-type animals [59]. 
Thus, these data strongly suggest the ADAM10 
CTF is a substrate for both PS1- and PS2-related 
γ-Secretases.
To confirm the release of ADAM10 ICDs from 
ADAM10 CTFs we introduced a VP16-GAL4 
sequence close to the C-terminus of the ICD 
domain (Fig 3 E) that would result in activation 
of transcription from a GAL4 upstream 
activation sequence (UAS)-luciferase reporter 
gene after being released from the membrane by 
-Secretase. Transfection of COS cells induced a 
tenfold activation of the luciferase reporter (Fig 
3 F, white bar in ADAM10-GAL), which was 
reduced by the -Secretase inhibitor X (inh X) to 
the level of DMSO controls (Fig 3 F red bar in 
ADAM10-GAL). Moreover, cotransfection with 
ADAM9 resulted in a ~100fold reporter 
activation as a result of the increased generation 
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6of the ADAM10 CTF available for processing 
by the -Secretase, effects that were entirely 
blocked by the -Secretase inhibitor X (Fig 3 F, 
yellow and blue bar, respectively). Thus, these 
results are consistent with reporter activation 
initiated by ectodomain cleavage of ADAM10 
via ADAM9 and consecutive RIP of the 
generated ADAM10 CTF by the -Secretase 
resulting in the release of the ADAM10 ICD.
RIP of ADAM10 leads to an intranuclear 
accumulation of its ICD 
Regulated intramembrane proteolysis of several 
proteins such as the Notch receptor is followed 
by nuclear translocation of the intracellular 
domain. Endogenous nuclear ADAM10 
immunoreactivity was below detection limits in 
purified nuclear fractions from MEF cells (Fig 4, 
lane 1), probably reflecting the low nuclear 
concentrations of the ADAM10 ICD, similar to 
the Notch receptor ICD [60]. However, addition 
of the nuclear export inhibitor leptomycin B 
(LMB) allowed specific detection of a ~4-5 kDa 
band in nuclear fractions that cross-reacted with 
ADAM10 carboxyterminal specific antibodies 
(Fig 4, lane 2). This band was not observed in 
nuclei purified from ADAM10-deficient cells 
(Fig 4, lane 3) or from cells deficient in ADAM9
and -15 or the -Secretase components PS1/2
(Fig 4, lanes 4-5, respectively). Interestingly, 
reintroduction of hPS1 into PS1/2-deficient cells 
rescued appearance of the ADAM10 ICD (Fig 4, 
lane 6). 
We then confirmed the nuclear localization of 
the ADAM10 ICD by transfecting HEK293 cells 
with an ADAM10E-FLAG construct (Fig 5 A), 
which is a membrane-anchored fragment of 
ADAM10 that requires γ-Secretase processing to 
release the ICD, but does not require the rate-
limiting ectodomain shedding step by ADAM9 
or 15. A similar construct has been used 
previously to study intramembrane proteolysis of 
Notch. We found that about 30% of the cells 
transfected with this construct (displaying strong 
cell surface immunofluorescence when stained 
with FLAG antibodies), exhibited nuclear 
immunoreactivity (Fig 5 B-C, F, white bar). 
When inhibitor X was used, this percentage 
dropped to 5% of the FLAG-positive cells, 
confirming that the -Secretase was necessary to 
release the ADAM10 ICD (Fig 5 D-F, black 
bar). More specifically, ADAM10 ICD 
immunoreactivity was visible in multiple intense 
spots in the nucleus (Fig 5 B-C), independent of 
nucleoli, nuclear envelope indentations and 
heterochromatin accumulations, as is shown by 
the respective B23, laminB and BrdU 
immunostainings (Fig 6 D-L). A fraction of the 
ADAM10 ICD speckle–like structures appear to 
be closely associated with two known nuclear 
speckle subtypes, Cajal bodies and PML bodies, 
as identified by immunoreactivity for p80/coilin 
and PML, respectively (Fig 6 M-R), but not with 
sc-35 speckles (Fig 6 A-C). Notably, both Cajal 
bodies and PML bodies have been shown to 
localize to actively transcribed gene loci, 
indirectly supporting a role for ADAM10 in 
gene transcription control [61, 62].
DISCUSSION
ADAM10 functions as a membrane-tethered 
protease, initiating the regulated intramembrane 
proteolysis (RIP) of proteins such as the 
Cadherins, the Notch receptor and its ligands,
and cytokine receptors. We demonstrate here 
that ADAM10 is not only executor of, but also 
subject to, regulated intramembrane proteolysis, 
being shed by related metalloproteases and 
subsequently cleaved by -Secretase.
We identified two ADAM proteases, i.e. 
ADAM9 and ADAM15, as sheddases 
responsible for ectodomain cleavage of 
ADAM10. To date, ADAM9 has been reported 
to cleave HB-EGF and APP in vitro; however,
ADAM9 knockout mice display no deficiency in 
shedding of these proteins [17]. In view of 
studies that suggest that members of the ADAM 
family can compensate for the absence of one or 
more family members [13-17], it is usually very 
difficult to precisely define the function of 
individual ADAMs, such as ADAM9. 
Nevertheless, given the reduced accumulation of 
the ADAM10 CTF in vivo in brains of ADAM9-
and ADAM9/15- deficient mice and the in vitro
evidence in MEF and COS cell lines, ADAM10 
appears to be an authentic ADAM9 substrate. 
We demonstrate here that ADAM15, using the 
same criteria, is also a putative ADAM10 
sheddase. While ADAM9 and 15 seem to be 
important ADAM10 sheddases, tissue blots from 
compound ADAM9/15 knockout animals, 
suggest that at least one other unidentified 
protease can cleave ADAM10 in its ectodomain 
in certain tissues. Importantly, ADAM10 is the 
first identified substrate for ADAM15, which 
has until now mainly been studied in the context 
of cell-cell interaction and cell migration, 
functions that are mediated by its disintegrin and 
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7cystein-rich domains [57, 63, 64]. 
ADAM10 shedding results in the release of a 
proteolytically active soluble sADAM10 
protease which is then available to function as a 
soluble protease and an ADAM10 CTF, which is 
then subject to RIP. Accumulation of the 
ADAM10 CTF in PS1- and to a greater extent in 
PS1/PS2- deficient fibroblasts indicates that the 
ADAM10 CTF is a substrate for -Secretase. 
PS2 deficiency in fibroblasts alone had 
quantitatively little or no effect, in agreement 
with the relatively minor contribution of PS2 to 
-Secretase activity in fibroblasts [56, 65].
ADAM10 CTF processing was reconstituted by 
expressing wild-type human PS1 in PS1/PS2 
double deficient MEFs, but not by expressing a 
catalytically inactive mutant hPS1, in which the 
catalytic aspartyl residues have been replaced by 
alanine [46]. Treatment with the -Secretase 
inhibitor X resulted in ADAM10-CTF 
accumulation. Finally, the accumulation of 
ADAM10-CTFs in brain, liver and lung tissue 
from PS1-/- and PS2-/- mice in vivo, firmly 
establishes ADAM10 as an authentic γ-Secretase 
substrate. 
To address the physiological significance of the 
sequential ADAM10 proteolytic processing, one 
option could obviously be that the 
intramembrane processing merely serves to 
remove the transmembrane fragments of 
ADAM10 after shedding of the soluble 
ectodomain. However, several indirect 
arguments suggest the possibility that the 
intracellular domain of ADAM10 exerts a 
nuclear function. First, we could demonstrate 
nuclear enrichment of the ADAM10 ICD 
following treatment with the nuclear export 
blocker leptomycin B. We further could 
demonstrate enhanced nuclear staining when we 
transfected HEK293 cells with a FLAG-tagged 
ADAM10 construct with a shortened 
ectodomain (ADAM10E-FLAG), which 
bypasses the rate-limiting ectodomain shedding 
step by ADAM9 or -15 [66]. Under these 
conditions, an intense multipunctate nuclear 
immunoreactivity for ADAM10 could be 
observed. Nuclear transport of the ADAM10 
ICD was reduced following treatment with -
Secretase inhibitors, providing additional 
evidence for RIP of ADAM10.  
Finally we demonstrate that within the nucleus, 
the ADAM10 ICD localizes to a nuclear 
speckle–like compartment, similar to what has 
been described for Notch- and APP-ICDs [67]. 
Speckles are interchromatin bodies that 
concentrate proteins involved in mRNA 
production, splicing, and maturation. 
Furthermore, a fraction of these ADAM10 ICD-
containing speckle–like structures appears to be 
closely associated with two known nuclear 
speckle subtypes, Cajal bodies and PML bodies. 
Both Cajal bodies and PML bodies are 
associated with actively transcribed gene loci 
involved in cell survival control [61, 62], 
providing further circumstantial evidence for a 
nuclear function of ADAM10. Recently, 
translocation and colocalization of an 
approximately 60 kDa enzymatically active form 
of ADAM10 with the androgen receptor in the 
nuclear fraction of a prostate cancer was 
observed [68], opening the debate as to how
these observations are interrelated with our 
observations of 4 kDa ADAM10 nuclear 
fragment. 
We conclude that regulated intramembrane 
proteolysis of ADAM10 and the nuclear 
accumulation of ADAM10 ICDs suggests a dual 
function for ADAM10 as a “disintegrin protease 
and signalling receptor“ which is an intriguing 
idea as it would suggest that proteases can also 
function as signalling molecules. Recently, other 
membrane – tethered proteases such as MT1-
MMP [69] and BACE1 [70] have been reported 
to undergo ectodomain shedding, and it may be 
speculated that other membrane proteases may 
have such dual functions as well. 
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FIGURE LEGENDS
Fig. 1. Ectodomain shedding of ADAM10 in MEFs. A. Model of the domain organization of 
ADAM10 which consists of a pro-domain (Pro) that is proteolytically removed in the TGN by pro-
protein convertases, a zinc-binding metalloprotease (Protease) domain, a disintegrin domain (Dis), 
which binds to integrin cell adhesion molecules, a cystein-rich domain (Cys), which can interact with 
cell surface proteoglycans and in some cases also contains a fusion peptide sequence, a variable stalk
region, a transmembrane (TM) domain and a cytoplasmic (Cyto) domain. Epitopes for C- (B42.1) and 
N-terminus (MAB946) specific antibodies are indicated. Ectodomain shedding (arrow) leaves a ~10 
kDa membrane-anchored CTF and releases a ~55 kDa soluble ectodomain (sADAM10). B. Western 
blot analysis of total wild-type (+/+) MEF cell extracts (CE) (50 µg/lane) shows a Pro-ADAM10 (~85
kDa) and a mature ADAM10 (ADAM10 FL, ~65 kDa) after prodomain removal. A third 10 kDa band 
is detectable (ADAM10 CTF) with B42.1, the C-terminal ADAM10 antibody, but not by MAB946, 
the N-terminal antibody. Additional bands (asterisk) are observed in wild- type cells, but not in 
ADAM10- deficient cells. These bands may represent ADAM10 splice variants (see 
http://www.genecards.org/cgi-bin/carddisp.pl?gene=ADAM10) or degradation products.  A secreted 
ADAM10 ectodomain (sADAM10) is observed in the culture supernatant (SN) (30 µg/lane), detected 
by MAB946, but not B42.1. C. Culture supernatant (SN) from WT MEFs was able to cleave a 
synthetic peptide containing the APP α-secretase cleavage site in a FRET assay. In MEFs lacking 
ADAM10 we observed a strong reduction in this cleavage compared to WT. D. ADAM10 CTFs are 
detected by Western blot analysis in cell lysates samples from both neuronal and glial cell cultures (30 
µg/lane). E. Western blot of total tissue extracts of E16.5 CD1 mouse embryos (50 µg/lane). 
ADAM10 CTFs were detected to a various extent in all tested organs. 
Fig. 2. ADAM10 ectodomain shedding is mediated by ADAMs 9 and 15. A. Western blots of total 
MEF cell extracts (CE)(50 µg/lane) and culture supernatants (SN) (30 µg/lane). Metalloprotease 
inhibitors TAPI-1 (25µM), TAPI-2 (25µM) and GM6001 (50µM) significantly reduce ADAM10 
processing.  B. Western blots of total MEF cell extracts (CE) and supernatants (SN). Levels of 
ADAM10 expression are similar in WT, ADAM9-/- or ADAM9/15-/- cells (panel 1). No ADAM9 and 
ADAM15 protein expression was detected in the respective single and double knockouts (panels 2 
and 3). Levels of both ADAM10 CTFs and sADAM10 are strongly reduced in ADAM9-/- MEFs 
(panels 4 and 7, lanes 4-6). Residual ADAM10 CTF accumulation and sADAM10 are strongly 
reduced in combined ADAM9/15-/- MEFs, but not completely abolished as demonstrated by the
longer exposure (overnight, O.N.) (panels 4 and 7, lanes 7-9). Note that the levels of ADAM10 CTFs 
vary independently of the constant PS1 expression levels (compare panels 4 and 5). The ADAM10 
CTF appears sometimes as a doublet band, potentially related to posttranslational modifications or 
alternative cleavage sites. C. Western blot of total cell extracts (CE) and cell supernatant (SN). 
Untransfected COS cells show the presence of low amounts of endogenously expressed ADAM10  
(panel 1, lanes 1-2) and ADAM9 (panel 2, lanes 1-2). Overexpression of ADAM9 alone or 
ADAM9EA does not affect ADAM10 expression (panel 1, lanes 3 and 4 respectively). In ADAM10
transfected cells (1 g), ADAM10 full-length protein, ADAM10 CTFs and sADAM10 are easily 
demonstrated (panels 3 and 6, lanes 5-7). Cotransfection of ADAM10 with increasing amounts of 
ADAM9 (panel 2; 0.1 g in lanes 14-15 and 1 g in lanes 8-10) causes a parallel increase in 
ADAM10 CTFs and sADAM10 (panels 3 and 6, lanes 14-15 and lanes 8-10). This increase was not 
observed when co-transfecting ADAM10 with different concentrations of the catalytically inactive 
ADAM9EA mutant (panels 3 and 6, lanes 16-17 and lanes 11-13). Expression levels of PS1 (panel 4) 
do not show major variations. The -actin Western blot and Coomassie stain reflect equal loading of 
proteins in both cell extract and supernatant samples (panels 5 and 7, respectively). D. Membrane 
extracts prepared from 5-day-old (P5), 4 weeks old (4wk) and 1 year old (1y) mice brains show a 
decrease in ADAM10-CTF formation in ADAM9 and ADAM9/15 knockouts, compared to age-
matched WT mice. 
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Fig. 3. Metabolism of the ADAM10 CTF depends on PS/-Secretase activity. A. Schematic 
representation of an ADAM10 CTF generated by ADAM9 or -15 processing. -Secretase cleavage of 
this CTF releases a soluble intracellular domain (ICD) from the membrane into the cytoplasm. Loss of 
-Secretase activity results in accumulation of the ADAM10 CTF. B. Western blots of total cell 
extracts from MEFs (50 µg/lane) probed with indicated antibodies. Cells were treated with the -
Secretase inhibitor Inh X (0.1µM).  ADAM10 CTFs and APP CTFs, a known -Secretase substrate, 
accumulate in the presence of Inh X. C. Western blots of PS1-/- (lane 2) and PS1/2-/- MEFs (lanes 4 
and 6) show ADAM10 CTF accumulation. Stable transfection of wild-type human PS1 (hPS1) into 
PS1/2-/- MEFs (lane 7), but not the catalytically inactive PS1 D257A or D385A mutants, can rescue 
generation of the ADAM10 CTF (lanes 8-9). D. Western blots of mouse tissue extracts and 
quantitative analysis of 3 experiments. ADAM10 CTF accumulation occurs in the PS1-deficient brain 
and lung and PS2-deficient liver. P values are indicated with asterisks (*:p<0.05; **:p<0.01; 
***:p<0.001). E. Schematic representation of the Luciferase reporter construct. A VP16 (activation 
domain) - GAL4 (binding domain) fusion sequence was cloned to the ADAM10 C-terminus. F. 
Luciferase assay on COS cells transfected with either empty control vector (ø,) or with ADAM10-
VP16-GAL4 or APP-C99-VP16-GAL4 as positive control. The luciferase-reporter, driven by the 
GAL4 upstream activation sequence (UAS), was measured in 3 experiments and expressed relative to 
luciferase activation. Transfection of ADAM10-GAL4 alone resulted in activation of luciferase 
expression (white bar). This effect was inhibited by the -Secretase inhibitor X at 0.1µM (Inh X, red 
bar). Cotransfection with ADAM9 (yellow bar) strongly stimulated luciferase expression, an effect 
which could be inhibited by Inh X (blue bar), demonstrating that the execution of signaling depends
on the combined action of ADAM9 and the γ-Secretase. Transfection of GAL4-VP16 fusion protein 
(p-GAL) directly drives luciferase expression strongly and is independent of -Secretase processing 
(red bar, presence of Inh X).
Fig. 4. The ADAM10 ICD translocates to the nucleus in MEFs. Western blots of membrane (M) and 
nuclear (N) extracts of the indicated fibroblast cell lines. ADAM10 holoprotein is observed in all 
lanes except for the ADAM10-/- cells (panel 1). ADAM 10 CTFs are present in total cell extracts of 
WT MEFs, absent in ADAM10-/- and in ADAM9/15-/- cells, and accumulate in PS1/2-/- MEFs (panel 
2). The ADAM10 ICD could be demonstrated in nuclear fractions of WT cells only after addition of 
Leptomycin B (LMB) (100 ng/ml, O.N., lanes 2-6) to block nuclear export and is not detectable in 
ADAM10-/-, ADAM9/15-/- or PS1/2-/- cells (panel 3). Reconstitution of PS1/2-/- cells with hPS1
(lane 6) restores ADAM10 ICD generation and detection in the nucleus.  Enrichment of Sp1 confirms 
the efficiency of LMB treatment (panel 4). 
Fig. 5. The ADAM10 ICD translocates to the nucleus in HEK293 cells transfected with ADAM10E-
FLAG. A. A schematic representation of the ADAM10E-FLAG construct with release of ADAM10-
ICD-FLAG to the nucleus following -Secretase cleavage. B-D. Immunofluorescence labeling of 
transfected HEK cells using anti-Flag primary and green fluorescent secondary antibodies (Alexa-488 
conjugated). FLAG immunoreactivity (green) was observed in the nuclei of about 30 % of transfected
cells (B-C). Notice the multipunctate staining pattern resembling that of nuclear speckles (C).  Cross-
section through a speckle at the position of the white line, shown in inset in (C), confirms the 
intranuclear presence of speckles. Less than 5% of transfected cells show nuclear staining in the 
presence of the -Secretase inhibitor (Inh X, 0.1µM) (D-E). Hoechst nuclear counterstain is in blue. 
Bar, 10 m. F. The number of speckled nuclei in presence or absence of Inh X (white bar, DMSO 
control; black bar, +Inh X) is represented by a bar graph relative to the number of transfected cells 
(means of 3 experiments). P value <0.001 (***).
Fig. 6. The ADAM10 ICD is localized to a nuclear speckle compartment but is not associated with sc-
35, B23, laminB or BrdU. ADAM10E-FLAG transfected HEK293 cells were fixed, and nuclear 
localization of the FLAG-tagged ADAM10 ICD (B, E, H, K, N, Q) was compared with established 
marker proteins of speckles (sc-23 in A), nucleoli (B23/nucleophosmin in D), nuclear membrane 
(lamin B in G), heterochromatin accumulations (BrdU in J), p80/coilin-positive Cajal bodies (Coilin 
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in M) and PML bodies (PML in P). Immunodetection was done as in Fig. 5. Nuclear ADAM10-
immunoreactivity was mainly concentrated in multiple intense spots that did not colocalize with sc-35 
speckles (merged panel in C), nucleoli (merged panel in F), nuclear membrane indentations (merged 
panel in I) or heterochromatin accumulations (merged panel in L). A fraction of ADAM10 positive 
speckles was shown to be closely associated with p80/coilin-positive Cajal bodies (merged panel in 
O) and PML bodies (merged panel in R). Insets in O and R represent enlargements and cross-sections 
in both X/Y and X/Z planes and confirm the close association of FLAG with coilin and PML, 
respectively. The white lines in O and R point towards the position of the corresponding vertical 
sections. Detection of primary antibodies was done with Cy3-, Cy2-, Alexa 546– and Alexa 488–
conjugated goat anti– rabbit or goat anti–mouse secondary antibodies (1/1,000 dilution). Bar, 10 m.
Supplemental Fig. COS cell co-transfection with ADAMs 10 and 15 in a similar experimental setup 
as Fig. 2 C shows a dose-dependent increase in sADAM10 generation (panel 6) but a variable effect 
on ADAM10 CTF generation (panel 3). No effect on sADAM10 was observed following co-
transfection with ADAM10 and the ADAM15EA mutant. Β-actin controls show equal protein loading 
in cell lysates. Coomassie staining reflects equal loading of proteins in cell supernatant samples.
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Fig. 1
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Fig. 2
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Fig. 3
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Fig. 4
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 5, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
19
Fig. 5
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Fig. 6
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Suppl. Fig.
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